Adherence and persistence to once-daily single-inhaler versus multiple-inhaler triple therapy among patients with chronic obstructive pulmonary disease in the USA: A real-world study
Source : https://www.resmedjournal.com/article/S0954-6111(22)00072-5/fulltext
Triple therapy comprising an inhaled corticosteroid, long-acting muscarinic antagonist, and long-acting β2 agonist (ICS/LAMA/LABA) is recommended for chronic obstructive pulmonary disease (COPD) patients at risk of exacerbation. Multiple-inhaler triple therapy...
Conclusions: COPD patients initiating single-inhaler FF/UMEC/VI had significantly improved adherence and persistence compared with MITT.
Duplicate Prescription Rates of Long-Acting Bronchodilator Inhalers
Background: Long-acting bronchodilator inhalers are widely used with or without inhaled corticosteroids (ICs) by patients with lung diseases. In Israel alone, there are 21 inhalers containing long-acting β2 agonists (LABAs)...
Conclusions: Nearly 2% of the patients treated with long-acting bronchodilators consumed different medications of the same pharmacologic group even when adherence was satisfactory. COPD patients are at higher risk for inhaler duplication. Clinical Trial Registration Number: 0151-20-COM1.
Discontinuation of Inhaled Corticosteroids from Triple Therapy in COPD: Effects on Major Outcomes in Real World Clinical Practice - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35392746/
Recent reports provide evidence-based guidelines for the withdrawal of inhaled corticosteroids (ICS) in COPD, but data on patients treated with ICS-based triple therapy are sparse and contradictory. We assessed the...
Conclusion:This large real-world study in the clinical setting of COPD treatment suggests that certain patients on triple therapy can be safely withdrawn from ICS and remain on bronchodilator therapy. As residual confounding cannot be ruled out, ICS discontinuation is not warranted for patients with multiple exacerbations and with very severe...
How the cost-effectiveness results change in the China health policy environment: an economic evaluation of glycopyrrolate/formoterol for the treatment of COPD
Source : https://www.tandfonline.com/doi/full/10.1080/13696998.2022.2043633
Abstract To investigate the cost-effectiveness of glycopyrrolate/formoterol compared with tiotropium bromide for the treatment of moderate-to-severe COPD in China and discuss the influence of healthcare policies on the economic evaluation....
Conclusion: GFF MDI could be seen as a cost-effective therapy compared with tiotropium bromide from the perspective of the Chinese health care sector. The healthcare policy in China has a positive impact on the improvement of the cost-effectiveness as the result of price reduction and could benefit more patients.
Effect of daily tiotropium on allergen-induced early asthmatic responses and airway inflammation
Source : https://www.annallergy.org/article/S1081-1206(22)00296-4/fulltext
Long-acting muscarinic antagonists (LAMAs) have been approved as add-on treatment for moderate-to-severe asthma; tiotropium as an individual inhaler, and umeclidinium in a combination inhaler. Data from ovalbumin sensitized and challenged...
Conclusion: Here we report results of a pilot investigation of the efficacy of regular use tiotropium on the allergen-induced EAR and T2 eosinophilic airway inflammation.